AiCuris seeks partners for antibacterial programs

November 24, 2016 Christoph Graener

AiCuris CEO Holger Zimmermann talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the company’s journey to becoming a clinical biotech company since being spun out of Bayer AG as a small research group a decade ago. Zimmermann highlights AiCuris’s anti-infectives development pipeline, the next big goals for the company and how new partners might fit into its plans. AiCuris already has an exclusive worldwide licensing agreement in place with Merck & Co. for its lead compound, letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of human cytomegalovirus (HCMV) infection in transplant recipients. AiCuris received a EUR 110 million upfront payment from Merck as part of this deal, which covers AiCuris’s novel portfolio of investigational HCMV medicines.


Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Dr. Holger Zimmermann – CEO, AiCuris


Previous Article
Janssen focuses cardiometabolic R&D on prevention, cure and interception

With readouts in trials of key drugs Invokana and Xarelto coming, Dr. James F. List of Janssen is also look...

Next Article
Karus CEO highlights niche indications for oncology innovation
Karus CEO highlights niche indications for oncology innovation

Karus Therapeutics CEO, Simon Kerry, discusses the company’s cancer-focused pipeline and its strategy of ta...